KuhlmannTMocciaMCoetzeeT, et al. Multiple sclerosis progression: Time for a new mechanism-driven framework. Lancet Neurol2023; 22(1): 78–88.
2.
PalaniHKArunachalamAKKulkarniU, et al. Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial. Mol Ther Oncol2025; 33(2): 200977.
3.
HudecekMEinseleH.Highjacking myeloma’s niche with beefed-up CAR-Ts. Blood2022; 139(26): 3671–3672.
4.
BiondiMTettamantiSGalimbertiS, et al. Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden. Blood2023; 141(21): 2587–2598.
